Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Find your brand’s edge, with dynamic competitive simulations

How the best teams in pharma stay at the top of their game

- PMLiVE

Johnson & Johnson’s Rybrevant granted EC approval for first-line NSCLC use

The drug was previously approved by the EU regulator for use after the failure of platinum-based therapy

- PMLiVE

Pfizer/BioNTech’s Omicron JN.1-adapted COVID-19 vaccine recommended by CHMP

The vaccine generated an improved response against several Omicron JN.1 sublineages

- PMLiVE

AbbVie announces CHMP recommendation for Tepkinly in follicular lymphoma

The blood cancer accounts for up to 30% of all non-Hodgkin lymphoma cases

- PMLiVE

Savara announces positive phase 3 results for molgramostim in rare lung disease

Autoimmune pulmonary alveolar proteinosis affects around one in every 150,000 people in the US

- PMLiVE

Taking a more mindful approach to meetings

Having a break between meetings can improve our well-being and the quality of our work

- PMLiVE

NICE recommends CSL Behring’s haemophilia B gene therapy Hemgenix

More than 2,000 people in the UK are currently living with the genetic bleeding disorder

- PMLiVE

AbbVie expands inflammatory disease pipeline with $250m Celsius acquisition

The deal includes an anti-TREM1 antibody that has completed a phase 1 study in inflammatory bowel disease

- PMLiVE

FDA publishes guidance on diversity action plans to improve enrolment in clinical trials

The guidance will help to enhance the understanding of a disease or medical product being studied

- PMLiVE

Scientists discover new form of gene editing to recombine and rearrange DNA

The bridge RNA system allows researchers to edit, delete and convert DNA recombinases without using CRISPR

- PMLiVE

GenAI for medical writers is here to stay (and it’s not as scary as we thought)

By Tom Wilson

- PMLiVE

Youth is served

Why are 18-year-olds concerned about healthcare?

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links